2. Search Result
Search Result
Results for "

collageninduced

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

1

Biochemical Assay Reagents

6

Peptides

1

Inhibitory Antibodies

8

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-76938
    Actarit

    4-Acetylaminophenylacetic acid; MS-932

    		 Others Inflammation/Immunology
    Actarit, an orally active antirheumatic compound, has the potential to treat type II collagen-induced arthritis .
    Actarit
  • HY-N3668
    Cyclomorusin

    Cyclomorusin A; Cyclomulberrochromene

    		 Others Cardiovascular Disease
    Cyclomorusin (Cyclomorusin A; Cyclomulberrochromene) is a prenylflavonoid with antiplatelet activity. Cyclomorusin also inhibits markedly collagen-induced platelet aggregation .
    Cyclomorusin
  • HY-153321
    NX-5948

    BTK-IN-24

    		 Btk PROTACs Inflammation/Immunology Cancer
    NX-5948 (BTK-IN-24) is an orally active chimeric targeting molecule (CTM) that induces specific BTK protein degradation by the cereblon E3 ligase (CRBN) complex without degradation of other cereblon neo-substrates. NX-5948 mediates potent anti-inflammatory activity via BTK degradation with resultant inhibition of B cell activation. NX-5948 exhibits potent tumor growth inhibition in TMD8 xenograft models that contain either wild-type BTK or BTKi-resistant mutations. NX-5948 is efficacious in a mouse collageninduced arthritis (CIA) model. NX-5948 can cross the blood brain barrier (BBB). NX-5948 is a PROTAC composed of the ligand for target protein, a linker, and a cereblon E3 ligase (CRBN) complex (Red: ligand for target protein; Blue: CRBN; Black: linker) .
    NX-5948
  • HY-N7619
    Xanthopurpurin

    Purpuroxanthin

    		 MMP Metabolic Disease
    Xanthopurpurin, an anthraquinone glycoside, isolated from the roots of Rubia akane, shows mainly strong inhibition of collagen-induced platelet aggregation .
    Xanthopurpurin
  • HY-123133
    PKSI-527

    		Kallikrein Inflammation/Immunology
    PKSI-527 is a new, highly selective plasma kallikrein inhibitor. PKSI-527 can suppress collagen-induced arthritis (CIA) by modifying the kallikrein-kinin system .
    PKSI-527
  • HY-119735
    Curcolone

    		Others Cardiovascular Disease
    Curcolone is a sesquiterpenoid that inhibits collagen-induced or arachidonic acid (AA)-induced platelet aggregation .
    Curcolone
  • HY-N9794
    Isoboldine

    		Others Inflammation/Immunology
    Isoboldine is a pyridine alkaloid. Isoboldine effectively alleviates inflammation and joint destruction in collagen-induced arthritis in mice .
    Isoboldine
  • HY-N7316
    Frangulin B

    		Others Inflammation/Immunology
    Frangulin B, a natural compound that can be isolated from Rhamnus formosana, is an antagonist of collagen-induced platelet aggregation and adhesion .
    Frangulin B
  • HY-N12514
    Cyclomulberrin

    		Others Cardiovascular Disease
    Cyclomulberrin is a extended flavonoid that shows inhibition of arachidonic acid (AA)- and collagen-induced platelet aggregation, with IC50 value of 128.2 μM .
    Cyclomulberrin
  • HY-P5003
    Collagen Type II Fragment

    		MMP Inflammation/Immunology
    Collagen Type II Fragment is an anti-inflammatory peptide that potently inhibits collagen-induced arthritis (CIA) in mice. Collagen Type II Fragment can be used for research on inflammation and immunity .
    Collagen Type II Fragment
  • HY-N1861
    3-O-Methylquercetin tetraacetate

    Quercetin 3-O-methyl ether peracetate

    		 P2Y Receptor Cardiovascular Disease Cancer
    3-O-Methylquercetin tetraacetate is an antiplatelet agent. 3-O-Methylquercetin tetraacetate has potent antiplatelet effect on arachidonic acid, collagen-induced and PAF-induced platelet aggregation .
    3-O-Methylquercetin tetraacetate
  • HY-162375
    AF299

    		Others Cardiovascular Disease
    AF299 can reduce collagen-related peptide-induced platelet Ca 2+ rises and collagen-induced platelet aggregation. AF299 can be used for research of antiplatelet research .
    AF299
  • HY-144390
    (S)-S007-1558

    GPVI antagonist 1

    		 Glycoprotein VI Cardiovascular Disease
    (S)-S007-1558 (compound 5) is a glycoprotein VI (GPVI) platelet receptor antagonist. (S)-S007-1558 inhibits collagen-induced platelet aggregation with an IC50 of 25.3 μM .
    (S)-S007-1558
  • HY-114221
    Org 48762-0

    UR13870

    		 p38 MAPK Inflammation/Immunology
    Org 48762-0 is a potent, orally active and selective p38 inhibitor with EC50 of 0.1 μM. Org 48762-0 reduces LPS-induced TNFα release and prevents bone damage in collagen-induced arthritis in mice .
    Org 48762-0
  • HY-105872
    Trifenagrel

    		Others Cardiovascular Disease
    Trifenagrel is a platelet aggregation inhibitor that inhibits the inducing effects of arachidonic acid (AA) and collagen. The ED50s of trifenagrel for inhibiting AA- and collagen-induced platelet aggregation in guinea pigs were 1.4 mg/kg and 9.4 mg/kg, respectively .
    Trifenagrel
  • HY-U00235
    SR121566A

    		Integrin Inflammation/Immunology
    SR121566A is a novel non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC50s of 46±7.5, 56±6 and 42±3 nM, respectively.
    SR121566A
  • HY-N12141
    Flaccidoside II

    		Apoptosis Inflammation/Immunology
    Flaccidoside II inhibits proliferation and induces apoptosis in Malignant peripheral nerve sheath tumors (MPNSTs) cell lines. Flaccidoside II ameliorates collagen-induced arthritis in mice. Flaccidoside II is an active triterpenoid saponin constituent from Anemone flaccida rhizome .
    Flaccidoside II
  • HY-108559
    L-161982

    		Prostaglandin Receptor Inflammation/Immunology
    L-161982 is a selective EP4 receptor antagonist. L-161982 completely blocks PGE2-induced ERK phosphorylation and cell proliferation of HCA-7 cells. L-161982 alleviates collagen-induced arthritis in mice .
    L-161982
  • HY-136990
    GLPG0259

    		Others Cancer
    GLPG0259 is a ATP-competitive inhibitor of MAPK-activated protein kinase 5 (MK5) with oral activity. GLPG0259 reduces inflammation and bone destruction in a mouse model of collagen-induced arthritis. GLPG0259 also inhibited the metastasis of prostate cancer (PCa) cells .
    GLPG0259
  • HY-135401
    VU6015929
    1 Publications Verification

    		 Discoidin Domain Receptor Inflammation/Immunology
    VU6015929 is a potent, selective and orally active dual discoidin domain receptor 1/2 (DDR1/2) inhibitor with IC50s of 4.67 nM and 7.39 nM, respectively. VU6015929 potently blocks collagen-induced DDR1 activation and collagen-IV production .
    VU6015929
  • HY-120041
    ND-2158

    		IRAK Cancer
    ND-2158 is a competitive IRAK4 inhibitor, with the Ki of 1.3 nM. ND-2158 suppresses LPS-induced TNF production in human white blood cells, alleviated collagen-induced arthritis, and blocked gout formation in mouse models. ND-2158 has antitumor activity in vivo .
    ND-2158
  • HY-129786
    LG 82-4-00

    		Others Cardiovascular Disease
    LG 82-4-00 is a thromboxane (TX) synthase inhibitor with an IC50 value of 1.1 μM. LG 82-4-00 can inhibit collagen-induced TXB2 formation and platelet aggregation in plasma. LG 82-4-00 can be used in studies related to thrombotic diseases .
    LG 82-4-00
  • HY-P4684
    Osteostatin

    PTHrP (107–111)

    		 PTHR Inflammation/Immunology
    Osteostatin, a fragment of parathyroid hormone-related protein (PTHrP) 107-111, promotes bone repair in animal models of bone defects and prevents bone erosion in inflammatory arthritis, inhibits collagen-induced arthritis and inhibits osteoclastic bone resorption directly. Osteostatin can be used for inflammation and immunology research .
    Osteostatin
  • HY-10999
    Trametinib
    Maximum Cited Publications
    182 Publications Verification

    GSK1120212; JTP-74057

    		 MEK Autophagy Apoptosis Cancer
    Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis .
    Trametinib
  • HY-10999A
    Trametinib (DMSO solvate)
    Maximum Cited Publications
    182 Publications Verification

    GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate)

    		 MEK Apoptosis Cancer
    Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis .
    Trametinib (DMSO solvate)
  • HY-10999R
    Trametinib (Standard)

    		MEK Autophagy Apoptosis Cancer
    Trametinib (Standard) is the analytical standard of Trametinib. This product is intended for research and analytical applications. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis .
    Trametinib (Standard)
  • HY-128530
    Tetrathiomolybdate

    		Cuproptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Tetrathiomolybdate, an orally active anti-copper agent, reduces copper levels in the body. Tetrathiomolybdate has a protective effect on collagen-induced arthritis in mice. Tetrathiomolybdate also reduces blood sugar, but has no effect on mice with hereditary diabetes (db/db). Tetrathiomolybdate inhibit angiogenesis, also shows antiangiogenic effects in malignant pleural mesothelioma .
    Tetrathiomolybdate
  • HY-155031
    MCI

    		Reactive Oxygen Species COX Inflammation/Immunology
    MCI alleviates inflammation by macrophage reprogramming via targeting ROS scavenging and COX-2 downregulation. MCI inhibits COX-2 with an IC50 value of 1.23 μM. MCI has significant anti-inflammatory effects in collagen-induced arthritis (CIA) models. MCI can be used in research for rheumatoid arthritis (RA) .
    MCI
  • HY-18164
    TASP0277308

    		LPL Receptor Inflammation/Immunology
    TASP0277308 is a highly selective S1P1 antagonist. TASP0277308 possesses immunomodulatory activities, including lymphopenia, a block in T cell egress from the thymus, marginal zone B cell displacement, and the upregulation of CD69 expression on lymphocytes. TASP0277308 can be used for the research of collagen-induced arthritis in mice .
    TASP0277308
  • HY-15798
    UNC2881

    		VSV TAM Receptor Cardiovascular Disease
    UNC2881 is an orally active and specific Mer kinase inhibitor, inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM. UNC2881 shows additional inhibition against Axl and Tyro with IC50s of 360 nM and 250 nM, respectively. UNC2881 potently inhibits collagen-induced platelet aggregation, can be used for pathologic thrombosis research .
    UNC2881
  • HY-122906
    JTE-952

    		c-Fms Inflammation/Immunology
    JTE-952 is a potent, oral active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC50 values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis .
    JTE-952
  • HY-123400A
    iso-Samixogrel

    iso-DTTX30; iso-DT-TX 30 SE

    		 Others Cardiovascular Disease
    Iso-Samixogrel (iso-DTTX30) is a combined thromboxane A2 receptor blocker and thromboxane synthetase inhibitor that exhibits potent antithrombotic activity. Iso-Samixogrel effectively eliminates recurrent arterial thrombus formation and inhibits collagen-induced platelet aggregation ex vivo. Iso-Samixogrel also prolongs sublingual bleeding time, demonstrating its biological efficacy in managing thrombosis.
    iso-Samixogrel
  • HY-163651
    (R)-Vorbipiprant

    (R)-CR6086

    		 Prostaglandin Receptor Inflammation/Immunology
    (R)-Vorbipiprant ((R)-CR6086) is an orally active antagonist for prostaglandin E2 receptor 4 (EP4) with Ki of 16.6 nM for human EP4. (R)-Vorbipiprant inhibits PGE2 (HY-101952)-induced cAMP production with an IC50 of 22 nM. (R)-Vorbipiprant exhibits immunomodulatory and anti-angiogenic activities, and ameliorates the collagen-induced arthritis in mice .
    (R)-Vorbipiprant
  • HY-N1887
    4-Allylcatechol
    1 Publications Verification

    Hydroxychavicol; 4-Allylpyrocatechol

    		 Bacterial Infection Cardiovascular Disease
    4-Allylcatechol (4-Allylpyrocatechol) is a xylan isolated from the root of Piper taiwanense. 4-Allylcatechol has a strong inhibitory activity against collagen-induced platelet aggregation (IC50=5.3 μM). In addition, 4-Allylcatechol has anti-tuberculosis activity against Mycobacterium tuberculosis H37Rv (MIC=27.6 μg/mL) .
    4-Allylcatechol
  • HY-110177
    SP-100030

    		NF-κB Inflammation/Immunology
    SP-100030 is a potent NF-κB and activator protein-1 (AP-1) double inhibitor (IC50s=50 and 50 nM, respectively). SP-100030 inhibits IL-2, IL-8, and TNF-alpha production in Jurkat and other T cell lines. SP-100030 decreases murine collagen-induced arthritis (CIA) .
    SP-100030
  • HY-162011
    GPR183 antagonist-2

    		EBI2/GPR183 Inflammation/Immunology
    GPR183 antagonist-2 (compound 32) is a selective GPR183 antagonist with good water solubility and excellent pharmacokinetic properties. GPR183 antagonist-2 significantly reduces paw and joint swelling and gene expression of pro-inflammatory cytokines (MCP-1, MMPs, and VEGF) in a collagen-induced arthritis (CIA) mouse model in a dose-dependent manner. GPR183 antagonist-2 can be used in the study of autoimmune diseases .
    GPR183 antagonist-2
  • HY-116262
    SCH 51866

    		Phosphodiesterase (PDE) Cardiovascular Disease Inflammation/Immunology
    SCH 51866 is a potent, selective and orally active inhibitor of PDE1 (IC50=70 nM) and PDE5 (IC50=60 nM). SCH 51866 inhibits collagen-induced aggregation of human washed platelets (IC50=10 μM), prevents neointimal formation in balloon catheter-injured carotid arteries of spontaneously hypertensive rats (SHR), and reduces blood pressure in SHR. SCH 51866 can be used in the study of hypertension .
    SCH 51866
  • HY-117622
    ND-2110

    		IRAK Inflammation/Immunology Cancer
    ND-2110 is a selective IRAK4 inhibitor (Ki: 7.5 nM). ND-2110 binds to the ATP pocket of IRAK4. ND-2110 targets the subset of activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL) cell lines with MYD88 L265P mutations,. ND-2110 inhibits LPS-induced TNF production, alleviates collagen-induced arthritis, and blocks gout formation in mouse models .
    ND-2110
  • HY-120050
    GK470

    		Phospholipase Inflammation/Immunology
    GK470 (compound 28) is an inhibitor of group IVA cytosolic phospholipase A2 (GIVA cPLA2) with an IC50 of 300 nM in vesicle assays. GK470 has anti-inflammatory activity, inhibiting the release of arachidonic acid in SW982 fibroblast-like synoviocytes with an IC50 value of 0.6 μM. GK470 exhibits comparable anti-inflammatory effects to Methotrexate (HY-14519) in a preventive collagen-induced arthritis model and significantly reduces plasma PGE2 levels .
    GK470
  • HY-167692
    JI069

    		Others Others
    JI069 is a novel JAK-STAT inhibitor that demonstrates potent activity in suppressing Th1, Th2, and Th17 differentiation while promoting iTreg differentiation. JI069 effectively inhibits STAT3 activation as well as the activation of other STATs, including STAT1, STAT5, and STAT6. JI069 has shown significant therapeutic potential in alleviating symptoms of collagen-induced arthritis in mice while inhibiting cytokine production from T cells and the phosphorylation of STAT3 in synovial cells.
    JI069
  • HY-101448
    TMI-1

    WAY-171318

    		 MMP Apoptosis Interleukin Related TNF Receptor Caspase Infection Neurological Disease Inflammation/Immunology Cancer
    TMI-1 (WAY-171318) inhibits TNF converting enzyme (TACE) (IC50 of 8.4 nM), ADAM-TS-4, ADAM-17 and various MMPs with oral activity. TMI-1 significantly suppresses the secretion of TNF-α , alleviating collagen-induced arthritis in mice. TMI-1 inhibits cancer cell proliferation, induces apoptosis through a caspase-dependent pathway. TMI-1 also reverses TRPV1 upregulation and lowers the levels of inflammatory factors (TNF-α、IL-1β、IL-6) in nerve cells, protecting against paclitaxel-induced neurotoxicity. TMI-1 leads to changes in pro-atherogenic lipoprotein profiles, but does not affect the progression of early lesions .
    TMI-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: